Bekaii-Saab, T. S., Van Cutsem, E., Tabernero, J., Siena, S., Yoshino, T., Nakamura, Y., … Strickler, J. H. (2023). MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+metastatic colorectal cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Bekaii-Saab, Tanios S., Eric Van Cutsem, Josep Tabernero, Salvatore Siena, Takayuki Yoshino, Yoshiaki Nakamura, Kanwal Pratap Singh Raghav, et al. “MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+metastatic colorectal cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Bekaii-Saab TS, Van Cutsem E, Tabernero J, Siena S, Yoshino T, Nakamura Y, et al. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+metastatic colorectal cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Bekaii-Saab, Tanios S., et al. “MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+metastatic colorectal cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Bekaii-Saab TS, Van Cutsem E, Tabernero J, Siena S, Yoshino T, Nakamura Y, Pratap Singh Raghav K, Cercek A, Heinemann V, Adelberg DE, Ramos J, Yang S, Andre T, Strickler JH. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023.